{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:23:29Z","timestamp":1772623409368,"version":"3.50.1"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Screening and monitoring of diabetes or dyslipidemia frequently involves a multi-step process requiring patients to obtain test requisitions from their primary care physician (PCP), followed by a laboratory visit and re-consultation. Point-of-care testing (POCT) for hemoglobin A\n            <jats:sub>1c<\/jats:sub>\n            (HbA\n            <jats:sub>1c<\/jats:sub>\n            ) and lipid panel can streamline the patient care pathway. This study assessed the budget impact of introducing Afinion\u2122 2 POCT (Abbott Rapid Diagnostics) from the Canadian and Italian societal perspectives.\n            <jats:bold>Methods:<\/jats:bold>\n            Budget impact models were developed for Canada and Italy over a 5-year time horizon (2025 to 2029). The analyses considered the screening and monitoring of diabetes or dyslipidemia for patients utilizing the public healthcare system and attending primary care, and included direct costs (testing, consultations) and indirect costs (productivity loss, transportation) based on published sources. The budget impact (BI) was calculated by comparing scenarios with and without POCT. All costs were adjusted to Canadian dollars ($) or 2024 Euros (\u20ac). Scenario analyses were conducted to explore the impact of alternative assumptions.\n            <jats:bold>Results:<\/jats:bold>\n            The 5-year cumulative BI was -$758,006,692 (-$50,709,964 direct, -$707,296,728 indirect) for HbA\n            <jats:sub>1c<\/jats:sub>\n            POCT and -$726,452,755 ($2,684,011 direct, -$729,136,766 indirect) for lipid panel POCT in Canada and -\u20ac1,380,658,764 (-\u20ac6,391,954 direct, -\u20ac1,374,266,809 indirect) for HbA\n            <jats:sub>1c<\/jats:sub>\n            POCT and -\u20ac851,792,115 (\u20ac55,962,879 direct, -\u20ac907,754,993 indirect) for lipid panel POCT in Italy. In both countries, cost savings for both the healthcare payer and patients were observed for HbA\n            <jats:sub>1c<\/jats:sub>\n            POCT, while costs savings were derived from patient indirect costs for lipid panel POCT. The analyses estimated that 1,558,062 and 1,501,260 PCP consultations in Canada, 4,962,338 and 1,951,026 PCP consultations in Italy were avoided with implementation of POCT for HbA\n            <jats:sub>1c<\/jats:sub>\n            and lipid panel, respectively. Scenario analyses demonstrated potential further cost savings with implementation of POCT in pharmacies.\n            <jats:bold>Conclusion:<\/jats:bold>\n            This study demonstrates that the adoption of Afinion 2 POCT for HbA\n            <jats:sub>1c<\/jats:sub>\n            and lipid panel can provide efficiencies to different types of healthcare systems through reducing PCP consultations, saving time and money for patients and providing cost savings for payers.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0208","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:44:17Z","timestamp":1739972657000},"source":"Crossref","is-referenced-by-count":1,"title":["Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion\u2122 2 in Canada and Italy"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-1675","authenticated-orcid":false,"given":"David","family":"Garcia","sequence":"first","affiliation":[{"name":"EVERSANA, 3228 South Service Road, Burlington, Ontario, Canada, L7N 3H8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ruffolo","sequence":"additional","affiliation":[{"name":"Abbott Rapid Diagnostics, 30 Schanzenstr, K\u00f6ln, Germany, 51063"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-9329","authenticated-orcid":false,"given":"Alicyia Walczyk","family":"Mooradally","sequence":"additional","affiliation":[{"name":"EVERSANA, 3228 South Service Road, Burlington, Ontario, Canada, L7N 3H8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5451-4670","authenticated-orcid":false,"given":"Anna","family":"Zhou","sequence":"additional","affiliation":[{"name":"EVERSANA, 3228 South Service Road, Burlington, Ontario, Canada, L7N 3H8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Lazaridis","sequence":"additional","affiliation":[{"name":"Abbott Rapid Diagnostics, 185 Corkstown Road, Ottawa, Ontario, Canada, K2H 8V4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Laurelli","sequence":"additional","affiliation":[{"name":"Abbott Rapid Diagnostics, 110 Viale Thomas Alva Edison, Sesto San Giovanni, MI, Italy, 2009"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes JM","year":"2013","unstructured":"Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol. Rev. 93(1), 137\u2013188 (2013).","journal-title":"Physiol. Rev."},{"key":"e_1_3_7_4_2","unstructured":"WHO. Global Report on Diabetes. (2016). Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241565257"},{"issue":"1","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-020-01200-7","article-title":"Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications","volume":"20","author":"Sun B","year":"2021","unstructured":"Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc. Diabetol. 20(1), 9 (2021).","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202306200","article-title":"Dyslipidemia","volume":"176","author":"Arvanitis M","year":"2023","unstructured":"Arvanitis M, Lowenstein CJ. Dyslipidemia. Ann. Intern. Med. 176(6), ITC81\u2013ITC96 (2023).","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol. 34(5), 575\u2013584 (2018).","journal-title":"Can. J. Cardiol."},{"issue":"12","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"e007954","DOI":"10.1136\/bmjopen-2015-007954","article-title":"Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database","volume":"5","author":"Asghari S","year":"2015","unstructured":"Asghari S, Aref-Eshghi E, Godwin M, Duke P, Williamson T, Mahdavian M. Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. BMJ Open 5(12), e007954 (2015).","journal-title":"BMJ Open"},{"key":"e_1_3_7_9_2","unstructured":"Public Health Agency of Canada. Framework for Diabetes in Canada. (2022). Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/framework-diabetes-canada.html"},{"issue":"1","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41(1), 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"issue":"9","key":"e_1_3_7_11_2","first-page":"2399","article-title":"Consensus Committee. Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation","volume":"30","year":"2007","unstructured":"Consensus Committee. Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 30(9), 2399\u20132400 (2007).","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"13721","DOI":"10.1038\/s41598-017-14172-8","article-title":"Impact of analytical and biological variations on classification of diabetes using fasting plasma glucose, oral glucose tolerance test and HbA1c","volume":"7","author":"Chai JH","year":"2017","unstructured":"Chai JH, Ma S, Heng D Impact of analytical and biological variations on classification of diabetes using fasting plasma glucose, oral glucose tolerance test and HbA1c. Sci. Rep. 7(1), 13721 (2017).","journal-title":"Sci. Rep."},{"issue":"5","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/clinchem\/hvad012","article-title":"The present and future of lipid testing in cardiovascular risk assessment","volume":"69","author":"White-Al Habeeb NMA","year":"2023","unstructured":"White-Al Habeeb NMA, Higgins V, Wolska A, Delaney SR, Remaley AT, Beriault DR. The present and future of lipid testing in cardiovascular risk assessment. Clin. Chem. 69(5), 456\u2013469 (2023).","journal-title":"Clin. Chem."},{"issue":"9","key":"e_1_3_7_14_2","first-page":"1","article-title":"Point-of-care hemoglobin A1c testing: a budget impact analysis","volume":"14","author":"Chadee A","year":"2014","unstructured":"Chadee A, Blackhouse G, Goeree R. Point-of-care hemoglobin A1c testing: a budget impact analysis. Ont. Health Technol. Assess. Ser. 14(9), 1\u201323 (2014).","journal-title":"Ont. Health Technol. Assess. Ser."},{"issue":"3","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/1932296816678263","article-title":"Impact of HbA1c testing at point of care on diabetes management","volume":"11","author":"Schnell O","year":"2017","unstructured":"Schnell O, Crocker JB, Weng J. Impact of HbA1c testing at point of care on diabetes management. J. Diabetes Sci. Technol. 11(3), 611\u2013617 (2017).","journal-title":"J. Diabetes Sci. Technol."},{"issue":"3","key":"e_1_3_7_16_2","first-page":"328","article-title":"Synergy between point-of-care testing and laboratory consolidations","volume":"32","author":"Trenti T","year":"2021","unstructured":"Trenti T. Synergy between point-of-care testing and laboratory consolidations. EJIFCC 32(3), 328\u2013336 (2021).","journal-title":"EJIFCC"},{"issue":"12","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/imj.15114","article-title":"Point-of-care testing of HbA1c, renal function and lipids in remote or disadvantaged regions","volume":"50","author":"Handrinos L","year":"2020","unstructured":"Handrinos L, Januszewski AS, Trimble E, Donelan N, Williams P, Jenkins AJ. Point-of-care testing of HbA1c, renal function and lipids in remote or disadvantaged regions. Intern. Med. J. 50(12), 1567\u20131571 (2020).","journal-title":"Intern. Med. J."},{"key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1472-6963-10-165","article-title":"The cost\u2013effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial","volume":"10","author":"Laurence CO","year":"2010","unstructured":"Laurence CO, Moss JR, Briggs NE The cost\u2013effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial. BMC Health Serv. Res. 10, 165 (2010).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_7_19_2","unstructured":"Canadian Institute for Health Information. An overview of physician payments and cost per service [updated 11\/17\/2022]. Available from: https:\/\/www.cihi.ca\/en\/health-workforce-in-canada-in-focus-including-nurses-and-physicians\/an-overview-of-physician"},{"issue":"4","key":"e_1_3_7_20_2","first-page":"1","article-title":"Italy: Health System Review","volume":"24","author":"Giulio de Belvis A","year":"2022","unstructured":"Giulio de Belvis A, Meregaglia M, Morsella A Italy: Health System Review. Health Syst. Transit. 24(4), 1\u2013236 (2022).","journal-title":"Health Syst. Transit."},{"key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1472-6963-9-41","article-title":"Trends in laboratory testing for diabetes in Ontario, Canada 1995\u20132005: a population-based study","volume":"9","author":"Wilson SE","year":"2009","unstructured":"Wilson SE, Lipscombe LL, Rosella LC, Manuel DG. Trends in laboratory testing for diabetes in Ontario, Canada 1995\u20132005: a population-based study. BMC Health Serv. Res. 9, 41 (2009).","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.diabres.2005.03.024","article-title":"Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study)","volume":"70","author":"Harris SB","year":"2005","unstructured":"Harris SB, Eko\u00e9 JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res. Clin. Pract. 70(1), 90\u201397 (2005).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"e_1_3_7_23_2","unstructured":"Redazione Diabete. Adesione alla terapia per il diabete [updated 31\/12\/2017]. Available from: https:\/\/www.diabete.com\/adesione-alla-terapia\/"},{"issue":"3","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.17269\/cjph.104.3783","article-title":"Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey","volume":"104","author":"Joffres M","year":"2013","unstructured":"Joffres M, Shields M, Tremblay MS, Connor Gorber S. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. Can. J. Public Health 104(3), e252\u2013e257 (2013).","journal-title":"Can. J. Public Health"},{"key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CEOR.S347085","article-title":"Prevalence and patient outcomes of adult primary hypercholesterolemia and dyslipidemia in the UK: longitudinal retrospective study using a primary care dataset from 2009 to 2019","volume":"14","author":"Bilitou A","year":"2022","unstructured":"Bilitou A, Were J, Farrer A, Rabe A, Ming SWY, Haq I Prevalence and patient outcomes of adult primary hypercholesterolemia and dyslipidemia in the UK: longitudinal retrospective study using a primary care dataset from 2009 to 2019. Clinicoecon. Outcomes Res. 14, 189\u2013203 (2022).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"4","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clinthera.2007.04.009","article-title":"Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis","volume":"29","author":"Petrella RJ","year":"2007","unstructured":"Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin. Ther. 29(4), 742\u2013750 (2007).","journal-title":"Clin. Ther."},{"key":"e_1_3_7_27_2","unstructured":"Statistics Canada. Annual Demographic Estimates: Canada Provinces and Territories (Total Population only). (2023). Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/91-215-x\/91-215-x2023001-eng.htm"},{"key":"e_1_3_7_28_2","unstructured":"Canadian Institute for Health Information. National Physician Database Historical Utilization \u2013 Data Tables (Table D.2.1) [updated 10\/26\/2023]. Available from: https:\/\/www.cihi.ca\/en"},{"key":"e_1_3_7_29_2","unstructured":"Agenzia Nazionale per i Servizi Sanitari Regionali. Analisi comparata delle cure primarie in Europa [updated 06\/07\/2022]. Available from: https:\/\/www.agenas.gov.it\/"},{"issue":"8","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"e0255992","DOI":"10.1371\/journal.pone.0255992","article-title":"Changes in the top 25 reasons for primary care visits during the COVID-19 pandemic in a high-COVID region of Canada","volume":"16","author":"Stephenson E","year":"2021","unstructured":"Stephenson E, Butt DA, Gronsbell J Changes in the top 25 reasons for primary care visits during the COVID-19 pandemic in a high-COVID region of Canada. PLOS One 16(8), e0255992 (2021).","journal-title":"PLOS One"},{"issue":"3","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40609-016-0072-2","article-title":"The Italian NHS, the public\/private sector mix and the disparities in access to healthcare","volume":"3","author":"Toth F","year":"2016","unstructured":"Toth F. The Italian NHS, the public\/private sector mix and the disparities in access to healthcare. Global Social Welfare 3(3), 171\u2013178 (2016).","journal-title":"Global Social Welfare"},{"issue":"1","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.9778\/cmajo.20140128","article-title":"Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional study","volume":"4","author":"Queenan JA","year":"2016","unstructured":"Queenan JA, Williamson T, Khan S Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional study. CMAJ Open 4(1), E28\u2013E32 (2016).","journal-title":"CMAJ Open"},{"issue":"1","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcjd.2017.10.004","article-title":"Screening for diabetes in adults","volume":"42","author":"Ekoe JM","year":"2018","unstructured":"Ekoe JM, Goldenberg R, Katz P. Screening for diabetes in adults. Can. J. Diabetes 42(Suppl. 1), S16\u2013S19 (2018).","journal-title":"Can. J. Diabetes"},{"key":"e_1_3_7_34_2","article-title":"Schedule of Benefits for Laboratory Services","author":"Ministry of Health","year":"2023","unstructured":"Ministry of Health. Schedule of Benefits for Laboratory Services. Ontario Ministry of Health (2023).","journal-title":"Ontario Ministry of Health"},{"issue":"8","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson GJ","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can. J. Cardiol. 37(8), 1129\u20131150 (2021).","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich AJ","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr. Rev. 43(4), 611\u2013653 (2022).","journal-title":"Endocr. Rev."},{"key":"e_1_3_7_37_2","article-title":"Point-of-care screening programs in community pharmacy practice: an innovative approach to improving patient care","author":"Papastergiou J","year":"2015","unstructured":"Papastergiou J. Point-of-care screening programs in community pharmacy practice: an innovative approach to improving patient care. Canadian Pharmacists Conference 2015.","journal-title":"Canadian Pharmacists Conference"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:45:16Z","timestamp":1739972716000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.57264\/cer-2024-0208"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0208","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"article-number":"e240208"}}